Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
1. Pelareorep shows 2.5x PFS and OS over standard treatments in KRAS mutant mCRC. 2. Viral replication and immune activation confirmed in multiple mCRC studies. 3. Company plans to advance registration pathway for pelareorep in mCRC patients. 4. Promising data supports pelareorep’s use in RAS-mutated GI tumors. 5. Investigator-sponsored trials to further explore pelareorep’s potential benefits.